Literature DB >> 19903809

Targeted molecular therapy for neuroblastoma: the ARF/MDM2/p53 axis.

Eugene Kim, Jason Shohet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19903809     DOI： 10.1093/jnci/djp376

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  13 in total

1.  Pediatric oncology: G-CSF counteracts chemotherapy toxicity in neuroblastoma.

Authors:  Heidi Russell; Jason M Shohet
Journal:  Nat Rev Clin Oncol       Date:  2010-11-23       Impact factor: 66.675

Review 2.  Neuroblastoma: molecular pathogenesis and therapy.

Authors:  Chrystal U Louis; Jason M Shohet
Journal:  Annu Rev Med       Date:  2014-10-27       Impact factor: 13.739

3.  G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic.

Authors:  Danielle M Hsu; Saurabh Agarwal; Ashley Benham; Cristian Coarfa; Denae N Trahan; Zaowen Chen; Paris N Stowers; Amy N Courtney; Anna Lakoma; Eveline Barbieri; Leonid S Metelitsa; Preethi Gunaratne; Eugene S Kim; Jason M Shohet
Journal:  Cancer Res       Date:  2013-05-16       Impact factor: 12.701

Review 4.  Nucleolus-derived mediators in oncogenic stress response and activation of p53-dependent pathways.

Authors:  Dariusz Stępiński
Journal:  Histochem Cell Biol       Date:  2016-05-03       Impact factor: 4.304

5.  WIP1 phosphatase as a potential therapeutic target in neuroblastoma.

Authors:  Mark Richter; Tajhal Dayaram; Aidan G Gilmartin; Gopinath Ganji; Sandhya Kiran Pemmasani; Harjeet Van Der Key; Jason M Shohet; Lawrence A Donehower; Rakesh Kumar
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

Review 6.  Neuroblastoma treatment in the post-genomic era.

Authors:  Maria Rosaria Esposito; Sanja Aveic; Anke Seydel; Gian Paolo Tonini
Journal:  J Biomed Sci       Date:  2017-02-08       Impact factor: 8.410

7.  Anticancer Effects of the Marine Sponge Lipastrotethya sp. Extract on Wild-Type and p53 Knockout HCT116 Cells.

Authors:  Kiheon Choi; Hyun Kyung Lim; Sung Ryong Oh; Woo-Hyun Chung; Joohee Jung
Journal:  Evid Based Complement Alternat Med       Date:  2017-01-03       Impact factor: 2.629

Review 8.  Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.

Authors:  Atif Zafar; Wei Wang; Gang Liu; Wa Xian; Frank McKeon; Jia Zhou; Ruiwen Zhang
Journal:  Cancer Lett       Date:  2020-09-29       Impact factor: 8.679

9.  Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achille's heel to be exploited for the therapy of MYCN-amplified neuroblastoma.

Authors:  Marialaura Petroni; Veronica Veschi; Alberto Gulino; Giuseppe Giannini
Journal:  Front Oncol       Date:  2012-10-12       Impact factor: 6.244

10.  A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma.

Authors:  Eveline Barbieri; Katleen De Preter; Mario Capasso; Peter Johansson; Tsz-Kwong Man; Zaowen Chen; Paris Stowers; Gian Paolo Tonini; Frank Speleman; Jason M Shohet
Journal:  PLoS One       Date:  2013-11-19       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.